Literature DB >> 31276772

Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders.

Maria Rosaria Domenici1, Antonella Ferrante2, Alberto Martire2, Valentina Chiodi2, Rita Pepponi2, Maria Teresa Tebano2, Patrizia Popoli2.   

Abstract

Adenosine A2A receptor (A2AR) is a G-protein coupled receptor that regulates several important functions in the central nervous system. Large amount of preclinical data suggests that the A2AR could represent a target for the development of new therapeutic strategies for different neuropsychiatric conditions. In this review we will recapitulate and discuss the most relevant studies on the role of A2ARs in neurodegenerative, neurodevelopmental and psychiatric diseases, which led to suggest a therapeutic use of A2AR agonists in certain diseases (Niemann-Pick disease, autism-spectrum disorders, schizophrenia) and A2AR antagonists in others (Alzheimer's disease, Parkinson's disease, attention-deficit hyperactivity disorder, fragile X syndrome, depression, anxiety). Moreover, we will try to analyze which are the main obstacles to the conduction of clinical trials with A2AR ligands for the treatment of neuropsychiatric disease.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenosine A(2A) receptor; Mood disorder; Neurodegenerative disease; Neurodevelopment; Niemann-pick disease; Schizophrenia

Year:  2019        PMID: 31276772     DOI: 10.1016/j.phrs.2019.104338

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  14 in total

1.  Adenosine protects D-galactose induced alterations in rat model of aging via attenuating neurochemical profile and redox status.

Authors:  Noreen Samad; Arooj Nasir; Muhammad Habib Ur Rehman; Sheraz Ahmed Bhatti; Imran Imran
Journal:  Metab Brain Dis       Date:  2022-07-23       Impact factor: 3.655

2.  Adenosine A2A receptors blockade attenuates dexamethasone-induced alterations in cultured astrocytes.

Authors:  Daniela Madeira; Liliana Dias; Patrícia Santos; Rodrigo A Cunha; Paula Agostinho; Paula M Canas
Journal:  Purinergic Signal       Date:  2022-04-27       Impact factor: 3.950

3.  Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stability.

Authors:  Thu Hang Lai; Magali Toussaint; Winnie Deuther-Conrad; Peter Brust; Rodrigo Teodoro; Sladjana Dukić-Stefanović; Daniel Gündel; Friedrich-Alexander Ludwig; Barbara Wenzel; Susann Schröder; Bernhard Sattler; Rareş-Petru Moldovan; Björn H Falkenburger; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-02       Impact factor: 9.236

4.  Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidine Derivatives as New Potent and Selective Adenosine A2A Receptor Inverse Agonists.

Authors:  Flavia Varano; Daniela Catarzi; Erica Vigiani; Fabrizio Vincenzi; Silvia Pasquini; Katia Varani; Vittoria Colotta
Journal:  Pharmaceuticals (Basel)       Date:  2020-07-24

5.  An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?

Authors:  Stefania Merighi; Tino Emanuele Poloni; Lucia Pelloni; Silvia Pasquini; Katia Varani; Fabrizio Vincenzi; Pier Andrea Borea; Stefania Gessi
Journal:  Front Pharmacol       Date:  2021-03-22       Impact factor: 5.810

6.  Protect Effects of Seafood-Derived Plasmalogens Against Amyloid-Beta (1-42) Induced Toxicity via Modulating the Transcripts Related to Endocytosis, Autophagy, Apoptosis, Neurotransmitter Release and Synaptic Transmission in SH-SY5Y Cells.

Authors:  Junli Feng; Gongshuai Song; Qing Shen; Xi Chen; Qingcheng Wang; Shunyuan Guo; Manman Zhang
Journal:  Front Aging Neurosci       Date:  2021-11-26       Impact factor: 5.750

Review 7.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

8.  Exercise-Induced Adaptations to the Mouse Striatal Adenosine System.

Authors:  Ella E Bauer; Trevor J Buhr; Carter H Reed; Peter J Clark
Journal:  Neural Plast       Date:  2020-01-28       Impact factor: 3.599

9.  Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia.

Authors:  Marta Valle-León; Luis F Callado; Ester Aso; María M Cajiao-Manrique; Kristoffer Sahlholm; Marc López-Cano; Concepció Soler; Xavier Altafaj; Masahiko Watanabe; Sergi Ferré; Víctor Fernández-Dueñas; José M Menchón; Francisco Ciruela
Journal:  Neuropsychopharmacology       Date:  2020-10-03       Impact factor: 7.853

Review 10.  Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders.

Authors:  Daniil Grinchii; Eliyahu Dremencov
Journal:  Int J Mol Sci       Date:  2020-12-15       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.